The biologic drug ramucirumab can also be administered as an angiogenesis inhibitor in metastatic CRC patients, and like bevacizumab, it is a fully humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the VEGFR-2 extracellular domain, blocking all VEGF ligands from binding to this target [18,19]. The gene discussed is VEGFA; the disease is colorectal carcinoma.